{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:46:42Z","timestamp":1765039602271,"version":"3.41.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review gives an overview of recently published articles on COVID-19 and gout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>People with gout are likely to be at an increased risk of poor outcomes after COVID-19 infection due to comorbid cardiometabolic conditions. The effects of chronic hyperuricemia on trained immunity, and the hyperinflammatory state induced by gout itself may also play a role. Frequent courses of glucocorticoids for gout flares may be associated with adverse outcomes after COVID-19 infection and reduced immunogenicity to the COVID-19 vaccination. Similarities between the pathophysiology of gout flares and the dysregulated inflammatory response of severe COVID-19 have been identified. Medications used in the treatment of gout, including colchicine and interleukin-1 inhibitors, have shown promise in the treatment of COVID-19 in clinical trials. Overall, the COVID-19 pandemic has had a negative impact on gout care, with patients reporting more difficulty with disease control, accessing medications and healthcare, and poorer quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The COVID-19 pandemic has created many challenges for people with gout. At present, there is a lack of guidance on the management of gout during the pandemic and paucity of research assessing outcomes of COVID-19 infection in people with gout.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000860","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:33:48Z","timestamp":1639564428000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Gout and the COVID-19 pandemic"],"prefix":"10.1097","volume":"34","author":[{"given":"Vicky","family":"Tai","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[{"name":"University of Queensland School of Clinical Medicine, Faculty of Medicine"},{"name":"Royal Brisbane & Women's Hospital, Metro North Hospital & Health Service, Herston Road, Herston, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2665-9913(21)00073-4","article-title":"Patients with gout: an under-recognized group at high risk of COVID-19","volume":"3","author":"Dalbeth","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X20966124","article-title":"Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey","volume":"12","author":"Singh","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/acr2.11252","article-title":"Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK Biobank","volume":"3","author":"Topless","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"R8-20250526","first-page":"73","article-title":"Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support","volume":"121","author":"Colvine","year":"2008","journal-title":"N Z Med J"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"m3731","DOI":"10.1136\/bmj.m3731","article-title":"Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study","volume":"371","author":"Clift","year":"2020","journal-title":"BMJ"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41591-020-01191-8","article-title":"Individual and community-level risk for COVID-19 mortality in the United States","volume":"27","author":"Jin","year":"2021","journal-title":"Nat Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia","volume":"294","author":"Cab\u0103u","year":"2020","journal-title":"Immunol Rev"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","article-title":"Asymptomatic hyperuricemia: a silent activator of the innate immune system","volume":"16","author":"Joosten","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"39884","DOI":"10.1038\/srep39884","article-title":"Soluble uric acid activates the NLRP3 inflammasome","volume":"7","author":"Braga","year":"2017","journal-title":"Sci Rep"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/annrheumdis-2014-206564","article-title":"Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra","volume":"75","author":"Cri\u015fan","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e0181100","DOI":"10.1371\/journal.pone.0181100","article-title":"A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: a pilot study","volume":"12","author":"Tanaka","year":"2017","journal-title":"PLoS One"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/rheumatology\/kes326","article-title":"Hyperuricemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout","volume":"52","author":"Grainger","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.kint.2020.07.019","article-title":"SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule","volume":"98","author":"Werion","year":"2020","journal-title":"Kidney Int"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13054-021-03616-3","article-title":"Serum uric acid, disease severity and outcomes in COVID-19","volume":"25","author":"Dufour","year":"2021","journal-title":"Crit Care"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.semarthrit.2020.06.015","article-title":"Advances in our understanding of gout as an auto-inflammatory disease","volume":"50","author":"Bodofsky","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12916-017-0922-5","article-title":"What makes gouty inflammation so variable?","volume":"15","author":"Terkeltaub","year":"2017","journal-title":"BMC Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"eabd5487","DOI":"10.1126\/scitranslmed.abd5487","article-title":"Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients","volume":"12","author":"Pierce","year":"2020","journal-title":"Sci Transl Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R27-20250526","article-title":"Response to: \u2018Correspondence on \u2019Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry\u2019 by Mulhearn et al","author":"Sch\u00e4fer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/art.41596","article-title":"American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3","volume":"73","author":"Mikuls","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-015-0663-9","article-title":"Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases - a longitudinal study","volume":"17","author":"Fischer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicenter study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.semnephrol.2020.12.001","article-title":"Pathophysiology of gout","volume":"40","author":"Narang","year":"2020","journal-title":"Semin Nephrol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/annrheumdis-2020-219174","article-title":"Anti-inflammatory therapy for COVID-19 infection: the case for colchicine","volume":"80","author":"Reyes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"e001455","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomized, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD Open"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomized, double-blinded, adaptive, placebo-controlled, multicenter trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized, multicenter, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomized controlled trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"e457-ee458","DOI":"10.1016\/S2665-9913(20)30167-3","article-title":"Canakinumab in a subgroup of patients with COVID-19","volume":"2","author":"Ucciferri","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"21775","DOI":"10.1038\/s41598-020-78492-y","article-title":"Blockage of interleukin-1\u03b2 with canakinumab in patients with Covid-19","volume":"10","author":"Landi","year":"2020","journal-title":"Sci Rep"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/acr.24487","article-title":"Management of rheumatic diseases during the COVID-19 pandemic: a national veterans affairs survey of rheumatologists","volume":"73","author":"Singh","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"SI77","DOI":"10.1093\/rheumatology\/keab174","article-title":"COVID-19 pandemic impact on people with rheumatic and musculoskeletal diseases: Insights from patient-generated health data on social media","volume":"60","author":"Reuter","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1016\/S2665-9913(21)00175-2","article-title":"Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviors: results from an international survey of people with rheumatic diseases","volume":"3","author":"Hausmann","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:17:17Z","timestamp":1748294237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000860","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"type":"print","value":"1040-8711"},{"type":"electronic","value":"1531-6963"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}